US Stock MarketDetailed Quotes

SNY Sanofi

Watchlist
  • 49.680
  • +0.490+1.00%
Trading Jan 7 15:29 ET
124.56BMarket Cap26.64P/E (TTM)

Sanofi Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Sanofi Q4 2024 Estimates Date

Currency：USDJan 30, 2025

Estimate YoY
Revenue
11.43B
-5.18%
EPS
0.54
+325.23%
Analyst Rating
Buy

Dec 31, 2024

Sanofi Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: EUR

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
Apr 24, 20252025/Q1-- / 10.960B--
Jan 30, 20252024/Q4-- / 10.982B--
Oct 25, 20242024/Q313.438B / 12.670B--
Jul 25, 20242024/Q210.745B / 10.377B--
Apr 25, 20242024/Q110.464B / 10.208B--
DatePeriodRevenue/EstimateEarnings Call
Apr 24, 20252025/Q1-- / 10.960B--
Jan 30, 20252024/Q4-- / 10.982B--
Oct 25, 20242024/Q313.438B / 12.670B--
Jul 25, 20242024/Q210.745B / 10.377B--
Apr 25, 20242024/Q110.464B / 10.208B--

Unlock Free Earnings Estimates

Sanofi Earnings Reports

  • 6-K: 15.7% Sales Growth Boosted by Earlier-Than-Anticipated Vaccine Sales; 2024 Business Eps Guidance Raised Due to Strong Business Performance

    Oct 25, 2024 12:42 ET

  • 6-K: Sanofi Reports Strong Second Quarter Results with 10% Sales Growth; 2024 Guidance Upgraded

    Jul 25, 2024 11:48 ET

  • 6-K: 2024 Half-Year Financial Report

    Jul 25, 2024 10:29 ET

  • Sanofi | 6-K: Colletion of Recent Announcements

    May 2, 2024 15:56 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 31, 2024

    Buy

    • Buy

      66.67%

    • Hold

      33.33%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Infectious Disease
    Infectious Disease
    Intraday+1.17%